RU2013133864A - Составы менингококковых вакцин - Google Patents

Составы менингококковых вакцин Download PDF

Info

Publication number
RU2013133864A
RU2013133864A RU2013133864/10A RU2013133864A RU2013133864A RU 2013133864 A RU2013133864 A RU 2013133864A RU 2013133864/10 A RU2013133864/10 A RU 2013133864/10A RU 2013133864 A RU2013133864 A RU 2013133864A RU 2013133864 A RU2013133864 A RU 2013133864A
Authority
RU
Russia
Prior art keywords
meningitidis
composition
lyophilized
kit
strain
Prior art date
Application number
RU2013133864/10A
Other languages
English (en)
Inventor
Марио Конторни
Джина КАЗЗАЗ
Дерек О'Хейган
Манмохан Сингх
Милдред УГОЗЗОЛИ
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2013133864A publication Critical patent/RU2013133864A/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

1. Лиофилизированная антигенная композиция, включающая (i) иммуноген для индукции иммунного ответа против Neisseria meningitidis серологической группы B и (ii) конъюгированный капсульный сахарид из Neisseria meningitidis одной или нескольких серологических групп A, C, W135 и/или Y.2. Композиция по п. 1, где лиофилизированная антигенная композиция содержит мембранные везикулы из штамма N. meningitidis серологической группы B.3. Композиция по п. 1, где лиофилизированная антигенная композиция содержит рекомбинантные белки штамма N. meningitidis серологической группы B.4. Композиция по п. 1, где лиофилизированная антигенная композиция содержит липоолигосахарид из штамма N. meningitidis серологической группы B.5. Композиция по п. 1, где лиофилизированная антигенная композиция по существу не содержит солей алюминия.6. Набор, содержащий два контейнера, где один контейнер включает жидкость для восстановления, и второй контейнер включает лиофилизированную композицию по любому из предыдущих пунктов.7. Набор по п. 6, где жидкость для восстановления включает жидкий адъювант.8. Набор по п. 7, где жидкий адъювант включает эмульсию типа масло-в-воде.

Claims (8)

1. Лиофилизированная антигенная композиция, включающая (i) иммуноген для индукции иммунного ответа против Neisseria meningitidis серологической группы B и (ii) конъюгированный капсульный сахарид из Neisseria meningitidis одной или нескольких серологических групп A, C, W135 и/или Y.
2. Композиция по п. 1, где лиофилизированная антигенная композиция содержит мембранные везикулы из штамма N. meningitidis серологической группы B.
3. Композиция по п. 1, где лиофилизированная антигенная композиция содержит рекомбинантные белки штамма N. meningitidis серологической группы B.
4. Композиция по п. 1, где лиофилизированная антигенная композиция содержит липоолигосахарид из штамма N. meningitidis серологической группы B.
5. Композиция по п. 1, где лиофилизированная антигенная композиция по существу не содержит солей алюминия.
6. Набор, содержащий два контейнера, где один контейнер включает жидкость для восстановления, и второй контейнер включает лиофилизированную композицию по любому из предыдущих пунктов.
7. Набор по п. 6, где жидкость для восстановления включает жидкий адъювант.
8. Набор по п. 7, где жидкий адъювант включает эмульсию типа масло-в-воде.
RU2013133864/10A 2007-10-19 2013-07-19 Составы менингококковых вакцин RU2013133864A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99959007P 2007-10-19 2007-10-19
US60/999,590 2007-10-19

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2010119947/10A Division RU2498815C2 (ru) 2007-10-19 2008-10-17 НАБОР ДЛЯ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ КОМПОЗИЦИИ ПРОТИВ Neisseria meningitidis СЕРОЛОГИЧЕСКОЙ ГРУППЫ В

Publications (1)

Publication Number Publication Date
RU2013133864A true RU2013133864A (ru) 2015-01-27

Family

ID=40428348

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2010119947/10A RU2498815C2 (ru) 2007-10-19 2008-10-17 НАБОР ДЛЯ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ КОМПОЗИЦИИ ПРОТИВ Neisseria meningitidis СЕРОЛОГИЧЕСКОЙ ГРУППЫ В
RU2013133864/10A RU2013133864A (ru) 2007-10-19 2013-07-19 Составы менингококковых вакцин

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2010119947/10A RU2498815C2 (ru) 2007-10-19 2008-10-17 НАБОР ДЛЯ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ КОМПОЗИЦИИ ПРОТИВ Neisseria meningitidis СЕРОЛОГИЧЕСКОЙ ГРУППЫ В

Country Status (20)

Country Link
US (2) US20100285069A1 (ru)
EP (2) EP2200642B1 (ru)
JP (3) JP5701058B2 (ru)
CN (1) CN101951949B (ru)
AT (1) ATE553774T1 (ru)
AU (1) AU2008313424B2 (ru)
BR (2) BR122016015627A2 (ru)
CA (2) CA2702871A1 (ru)
CO (1) CO6270339A2 (ru)
CY (1) CY1112908T1 (ru)
DK (1) DK2200642T3 (ru)
ES (1) ES2383231T3 (ru)
HR (1) HRP20120433T1 (ru)
MX (2) MX2010004271A (ru)
NZ (1) NZ584683A (ru)
PL (1) PL2200642T3 (ru)
PT (1) PT2200642E (ru)
RU (2) RU2498815C2 (ru)
SI (1) SI2200642T1 (ru)
WO (1) WO2009050586A1 (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CA2688268A1 (en) * 2007-06-04 2008-12-11 Novartis Ag Formulation of meningitis vaccines
US20100189737A1 (en) * 2008-12-17 2010-07-29 Arico Beatrice Meningococcal vaccines including hemoglobin receptor
AU2010290896B2 (en) 2009-09-02 2014-07-03 Glaxosmithkline Biologicals S.A. Immunogenic compositions including TLR activity modulators
RU2580620C2 (ru) * 2010-08-23 2016-04-10 ВАЙЕТ ЭлЭлСи СТАБИЛЬНЫЕ КОМПОЗИЦИИ АНТИГЕНОВ Neisseria meningitidis rLP2086
ES2458355T3 (es) 2010-09-01 2014-05-05 Novartis Ag Adsorción de inmunopotenciadores sobre sales metálicas insolubles
PE20140173A1 (es) 2010-09-10 2014-02-20 Wyeth Llc Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis
BR112013022397A2 (pt) 2011-03-02 2017-09-26 Derek O’Hagan vacinas combinadas com doses menores de antígeno e/ou adjuvante
US9283270B2 (en) * 2012-01-20 2016-03-15 Serum Institute Of India Ltd. Method for stabilization of biological molecules
PL2822947T3 (pl) 2012-03-07 2017-01-31 Glaxosmithkline Biologicals Sa Sole argininowe agonisty TLR7
AU2013229432A1 (en) 2012-03-08 2014-10-16 Novartis Ag Adjuvanted formulations of booster vaccines
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
CN104736563A (zh) 2012-07-27 2015-06-24 国家健康与医学研究院 Cd147作为受体用于脑膜炎球菌至血管内皮的菌毛介导的粘附
EP2964665B1 (en) 2013-03-08 2018-08-01 Pfizer Inc Immunogenic fusion polypeptides
MX369534B (es) 2013-09-08 2019-11-11 Pfizer Composiciones de neisseria meningitidis y sus metodos.
CN107249626A (zh) 2015-02-19 2017-10-13 辉瑞大药厂 脑膜炎奈瑟球菌组合物及其方法
MX2019002489A (es) 2016-09-02 2019-10-21 Sanofi Pasteur Inc Vacuna contra neisseria meningitidis.
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
CN111278458A (zh) * 2017-10-25 2020-06-12 默沙东公司 佐剂疫苗

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US4803070A (en) * 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
US5204098A (en) 1988-02-16 1993-04-20 The United States Of America As Represented By The Department Of Health And Human Services Polysaccharide-protein conjugates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
NL8802046A (nl) 1988-08-18 1990-03-16 Gen Electric Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen.
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
JPH04506662A (ja) 1989-07-14 1992-11-19 アメリカン・サイアナミド・カンパニー 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
ATE128628T1 (de) 1990-08-13 1995-10-15 American Cyanamid Co Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff.
IL101007A (en) 1992-02-18 1997-08-14 Pharmos Ltd Dry stable compositions prepared by lyophilization
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
US5425946A (en) 1992-08-31 1995-06-20 North American Vaccine, Inc. Vaccines against group C Neisseria meningitidis
PT658118E (pt) 1992-08-31 2002-05-31 Baxter Healthcare Sa Vacinas contra neisseria meningitidis do grupo c
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
GB9422096D0 (en) * 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
AU7701098A (en) 1997-05-28 1998-12-30 Michael A. Apicella Laft mutants of pathogenic gram-negative bacteria
GB9711964D0 (en) 1997-06-09 1997-08-06 Medical Res Council Live attenuated vaccines
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
ATE384130T1 (de) 1997-08-21 2008-02-15 Nederlanden Staat Neue mutanten der gram-negativen mukosalen bakterien und ihre verwendung als impfstoffe
AU9363798A (en) 1997-11-06 1999-05-31 Chiron S.P.A. Neisserial antigens
CA2317815A1 (en) 1998-01-14 1999-07-22 Chiron S.P.A. Neisseria meningitidis antigens
WO1999040188A2 (en) * 1998-02-05 1999-08-12 Smithkline Beecham Biologicals S.A. Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccinations
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US6645503B1 (en) 1998-03-10 2003-11-11 Wyeth Holdings Corporation Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria
ES2304065T3 (es) 1998-05-01 2008-09-01 Novartis Vaccines And Diagnostics, Inc. Antigenos y composiciones de neisseria meningitidis.
ES2278446T3 (es) * 1998-05-29 2007-08-01 Novartis Vaccines And Diagnostics, Inc. Vacunas combinadas b/c contra la meningitis.
EP1741443B1 (en) * 1998-05-29 2014-05-21 Novartis Vaccines and Diagnostics, Inc. Combination meningitidis B/C vaccines
EP1109576B1 (en) 1998-08-19 2009-10-21 Baxter Healthcare SA Immunogenic beta-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an n-acryloylated polysaccharide
AU1202200A (en) 1998-10-09 2000-05-01 Chiron Corporation Neisseria genomic sequences and methods of their use
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
AU762369B2 (en) 1998-11-03 2003-06-26 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur LPS with reduced toxicity from genetically modified gram negative bacteria
AU1626199A (en) 1998-12-04 2000-06-26 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A vi-repa conjugate vaccine for immunization against salmonella typhi
EP1880735A3 (en) 1999-03-19 2008-03-12 GlaxoSmithKline Biologicals S.A. Vaccine
JP2002541808A (ja) 1999-04-09 2002-12-10 テクラブ, インコーポレイテッド ポリサッカリド結合体ワクチンのための組換えトキシンaタンパク質キャリア
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
US6531131B1 (en) 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
GB9925559D0 (en) 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
AU1917501A (en) 1999-11-12 2001-06-06 University Of Iowa Research Foundation, The Control of neisserial membrane synthesis
DK2289545T3 (en) 2000-01-17 2016-09-05 Glaxosmithkline Biologicals Sa Supplemented OMV vaccine against meningococcus
CN100473663C (zh) 2000-02-28 2009-04-01 启龙股份公司 奈瑟球菌蛋白质的异源表达
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
CA2416137C (en) 2000-07-27 2013-01-29 Dan Granoff Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
JP2005504718A (ja) 2001-01-23 2005-02-17 アヴェンティス パストゥール 多価髄膜炎菌多糖−タンパク質複合ワクチン
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
AU2002309706A1 (en) 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MXPA04009339A (es) 2002-03-26 2005-01-25 Chiron Srl Sacaridos modificados que tienen estabilidad mejorada en agua.
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
GB0213622D0 (en) 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
JP2006500963A (ja) 2002-08-02 2006-01-12 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン組成物
GB0218821D0 (en) * 2002-08-13 2002-09-18 Glaxosmithkline Biolog Sa Novel compositions
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
CA2823937A1 (en) * 2002-10-07 2004-04-22 Novartis Vaccines And Diagnostics, Inc. Hiv vaccine formulations
AU2003274511B2 (en) 2002-10-11 2009-06-04 Glaxosmithkline Biologicals S.A. Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
DK2279746T3 (da) * 2002-11-15 2013-11-25 Novartis Vaccines & Diagnostic Overfladeproteiner i neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
WO2004067030A2 (en) * 2003-01-30 2004-08-12 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
CA2521050A1 (en) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations and related methods of use
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
ES2397923T3 (es) * 2003-10-02 2013-03-12 Novartis Ag Vacunas líquidas para múltiples serogrupos meningocócicos
EP1706481A2 (en) * 2003-12-23 2006-10-04 GlaxoSmithKline Biologicals S.A. Vaccine
KR20070008625A (ko) 2004-04-05 2007-01-17 화이자 프로덕츠 인코포레이티드 미세유체화된 수중유 유화액 및 백신 조성물
GB0409745D0 (en) * 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
WO2007013893A2 (en) * 2004-11-15 2007-02-01 Novartis Vaccines And Diagnostics Inc. Immunogenic compositions containing anthrax antigen, biodegradable polymer microparticles, and polynucleotide-containing immunological adjuvant
EP2682126B1 (en) 2005-01-27 2016-11-23 Children's Hospital & Research Center at Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
WO2006100111A1 (en) 2005-03-23 2006-09-28 Glaxosmithkline Biologicals S.A. Composition
US20060228369A1 (en) 2005-04-11 2006-10-12 Program For Appropriate Technology In Health Stabilization and preservation of temperature-sensitive vaccines
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
US8156755B2 (en) * 2005-06-03 2012-04-17 Intervet International B.V. Refrigerator for storing vials and cartridge for use in the same
MX2007016403A (es) 2005-06-27 2008-03-07 Glaxosmithkline Biolog Sa Composicion inmunogenica.
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
AR058592A1 (es) 2005-12-22 2008-02-13 Glaxosmithkline Biolog Sa Vacuna
EP1991204A2 (en) * 2006-02-24 2008-11-19 Novartis AG Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
CA2688268A1 (en) * 2007-06-04 2008-12-11 Novartis Ag Formulation of meningitis vaccines

Also Published As

Publication number Publication date
BRPI0818545A2 (pt) 2017-07-04
PT2200642E (pt) 2012-05-30
CN101951949B (zh) 2013-10-02
MX340096B (es) 2016-06-27
US20160228529A1 (en) 2016-08-11
CY1112908T1 (el) 2016-04-13
JP2013216704A (ja) 2013-10-24
RU2010119947A (ru) 2011-11-27
JP5701058B2 (ja) 2015-04-15
HRP20120433T1 (en) 2012-07-31
JP2011500662A (ja) 2011-01-06
AU2008313424A1 (en) 2009-04-23
CN101951949A (zh) 2011-01-19
US20100285069A1 (en) 2010-11-11
CA2925217A1 (en) 2009-04-23
WO2009050586A1 (en) 2009-04-23
CO6270339A2 (es) 2011-04-20
CA2702871A1 (en) 2009-04-23
DK2200642T3 (da) 2012-07-16
ATE553774T1 (de) 2012-05-15
RU2498815C2 (ru) 2013-11-20
JP2016029108A (ja) 2016-03-03
JP5925736B2 (ja) 2016-05-25
EP2462949A2 (en) 2012-06-13
MX2010004271A (es) 2010-05-03
BR122016015627A2 (pt) 2018-10-30
EP2200642B1 (en) 2012-04-18
AU2008313424B2 (en) 2014-05-22
EP2200642A1 (en) 2010-06-30
PL2200642T3 (pl) 2012-09-28
EP2462949A3 (en) 2012-09-05
SI2200642T1 (sl) 2012-06-29
ES2383231T3 (es) 2012-06-19
NZ584683A (en) 2012-05-25

Similar Documents

Publication Publication Date Title
RU2013133864A (ru) Составы менингококковых вакцин
RU2006114677A (ru) Жидкие вакцины для множественных серогрупп менингококков
Saukkonen et al. Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay
Sanders et al. Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines
RU2009149359A (ru) Состав вакцин против менингита
ES2278446T3 (es) Vacunas combinadas b/c contra la meningitis.
JP2011500662A5 (ru)
MX348734B (es) Vacunacion multiple que incluye meningococcus del serogrupo c.
JP2014506916A5 (ru)
RU2010138815A (ru) МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHBP
JP2011042693A5 (ru)
DE602005015961D1 (de) Kombinierte meningokokken-konjugate mit gemeinsamen trägerprotein
RU2004136299A (ru) Мукозальные вакцины с хитозановым адъювантом и/или антигенами менингококков
JP2007516219A5 (ru)
RU2007102016A (ru) Пространственный анализ конъюгатов сахаридов с помощью gpc и sec-mals
RU2013144207A (ru) Комбинированные вакцины с пониженными дозами антигена и/или адъюванта
AR046840A1 (es) Polisacaridos capsulares de neisseria meningitidis como inmunopotenciadores mucosales y formulaciones resultantes
RU2015100889A (ru) Вакцины для менингококка серогруппы х
RU2494758C2 (ru) Нейссериальные вакцинные композиции, содержащие комбинацию антигенов
Beuvery Immunisation against bacterial meningitis
STANDARDIZATION Response to Vaccine Antigens
EP4249061A3 (en) Immunogenic compositions against enteric diseases and methods for its preparation thereof
AU2012200061B2 (en) Multivalent meningococcal derivatized polysaccharide-protein conjugates and corresponding vaccines
Petousis-Harris et al. 2012 antigen review for the New Zealand national immunisation schedule: Meningococcal B and C
Borrow et al. The future of meningococcal vaccines

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20171117